Image of Zara Sproul

Zara Sproul

Senior Associate

Email

zara.sproul@aoshearman.com

Phone

+44 20 3088 5047

Offices

London

V-CARD
Zara advises on a range of corporate transactions including private acquisitions, public takeovers, equity finance and general corporate advisory work.
 

Zara has a particular focus on the Life Sciences, Consumer and Retail sectors, and is lead relationship associate for two publicly listed life sciences/consumer clients. Zara spent six months on secondment to a publicly listed Life Sciences client in 2020 and also 6 months on secondment to Allen & Overy's Madrid office.
 
Zara is co-lead of the Afghan Pro Bono Initiative project, for which she won the firm's prizes for “Access to Justice” and “Multijurisdictional Pro Bono Effort” in 2022. The project also won the 2022 LawWorks Award for Most Effective Pro Bono Partnership, and was highly commended at The Lawyer awards for “Pro Bono Initiative of the Year” in 2023.

Expertise

Industries

Experience

Representative matters

  • Wittington Investments on the c. GBP4bn sale of Selfridges, De Bijenkorf, Brown Thomas and Arnotts in Europe. 
  • Marks and Spencer plc on the acquisition of its logistics provider, Gist, in the UK.
  • A global healthcare company on the buyout of its Saudi Arabian joint venture partner. 
  • A global healthcare company on its divestment of 15 consumer healthcare brands to STADA.
  • EQT Infrastructure VI fund on its acquisition of a 60% stake in a new newly created company which will own and operate the Italian telecom provider Wind Tre’s mobile and fixed network. The remaining 40 per cent stake will be held by Wind Tre’s current owner, CK Hutchison. The enterprise value of the new company is EUR 3.4billion.
  • Christies on the sale of its real estate business.
  • Majestic Wine on the disposal of its retail and commercial business to Fortress Investment Group.
  • Campari Group on the acquisition of the Picon brand from Diageo.
  • BTG plc a global healthcare company, on the recommended offer by Boston Scientific Corporation, a US medical technology company for USD 4.3 billion.
  • Sirius Minerals plc on its distressed takeover by Anglo American plc for GBP 405 million, and advice on various strategic alternatives.
  • Shionogi on its joint venture with Apnimed for the development of therapies for sleep disorders.
  • Shionogi on its strategic collaboration with F2G to develop and commercialise Olorofim in Europe.
  • Zuellig Pharma on its acquisition of Cialis and Alimta from Eli Lilly in Asia.
  • Haleon plc on its divestment of antifungal brand Lamisil to Karo Healthcare in 75 markets.

Pro bono

  • Advising a number of Afghan nationals in the UK through the Afghan Pro Bono Initiative (a collaboration between law firms to provide legal representation for Afghan refugees).
  • Advice to individual client fleeing persecution in Iraq, leading to successful asylum in Australia.

Published Work

  • Drug formulations in life sciences transactions – https://www.aoshearman.com/en-gb/global/news-and-insights/publications/ao-hosts-webinar-on-drug-formulations-in-life-sciences-transactions
  • Global Impact of Covid-19 coronavirus on “non-Covid” clinical trials - https://www.aolifescienceshub.com/global-impact-of-covid-19-coronavirus-on-non-covid-clinical-trials/
  • COVID-19 and the life sciences sector - https://uk.practicallaw.thomsonreuters.com/w-025-9794?originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)

Qualifications

Admissions

Admitted as a Solicitor (England and Wales) 2018

Academic

Bachelor of Arts, Geography, University of Leeds, 2013
 
Graduate Diploma in Law, BPP University, 2015
 
Legal Practice Course, BPP University, 2016  

Disclaimer
A&O Shearman was formed on May 1, 2024 by the combination of Shearman & Sterling LLP and Allen & Overy LLP and their respective affiliates (the legacy firms). Any matters referred to above may include matters undertaken by one or more of the legacy firms rather than A&O Shearman.